argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has signed a strategic partnership with Monash University. Having opened its Australian affiliate office in early 2025, the partnership marks the company’s first partnership with Monash and its second research and development partnership in Australia.
The collaboration will see argenx and Monash advance an antibody molecule in pre-clinical development, with the shared ambition of one day addressing diseases with significant unmet need for patients. “Australia has built a world-class environment for innovative research,” argenx Australia General Manager Kathryn Evans said.
“This collaboration with Monash University reflects our continued interest in engaging deeply with Australia’s research community and learning from the scientific rigour and creativity that exists here. I’m looking forward to partnering with a team that values open exchange, long-term perspective and a shared commitment to advancing science in service of patients.”
Dr Ingmar Wahlqvist, Acting Chief Commercialisation Officer at Monash University, said: “This partnership is an excellent demonstration of what’s possible when leading researchers and industry partners come together with a shared commitment to achieving impact in areas of significant unmet need.”
Wahlqvist added: “We are excited by this combination of Monash’s research expertise and argenx’s global development capabilities. It highlights Monash’s commitment to industry collaboration, especially when it has the potential to deliver positive benefits for patients worldwide, and long-term value for both organisations.”
Initiated as part of argenx’s Immunology Innovation Program (IIP), the partnership will span key milestones from early-stage research, with the goal of reaching clinical trials and registration. Through its IIP, argenx works closely with leading scientists around the world to source novel biology that may lead to treatments for patients living with rare and underserved immunological conditions.
Archer completes potassium sensing alpha prototype
Quantum technology company Archer Materials Limited has developed an early Biochip prototype...
Farm animals and aquaculture cryopreservation partnership announced
Vitrafy Life Sciences Limited has announced that it has entered a 12-month exclusive agreement...
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
